{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:38Z","timestamp":1793289758658,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T00:00:00Z","timestamp":1340928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Orthop Surg Traumatol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00590-012-1035-7","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T14:53:43Z","timestamp":1340895223000},"page":"497-506","source":"Crossref","is-referenced-by-count":21,"title":["Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population"],"prefix":"10.1007","volume":"23","author":[{"given":"Zhi-han","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,29]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/ard.59.12.985","volume":"59","author":"J Braun","year":"2000","unstructured":"Braun J, Khan MA, Sieper J (2000) Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis 59:985\u2013994","journal-title":"Ann Rheum Dis"},{"key":"1035_CR2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0889-857X(05)70038-7","volume":"24","author":"J Braun","year":"1998","unstructured":"Braun J, Bollow M, Sieper J (1998) Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 24:697\u2013735","journal-title":"Rheum Dis Clin North Am"},{"key":"1035_CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/art.1780220408","volume":"22","author":"ET Carter","year":"1979","unstructured":"Carter ET, McKenna CH, Brian DD, Kurland LT (1979) Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935\u20131973. Arthritis Rheum 22:365\u2013370","journal-title":"Arthritis Rheum"},{"key":"1035_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00296-002-0237-4","volume":"23","author":"E Feldtkeller","year":"2003","unstructured":"Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23:61\u201366","journal-title":"Rheumatol Int"},{"key":"1035_CR5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.23704","volume":"59","author":"MM Ward","year":"2008","unstructured":"Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 59:822\u2013832","journal-title":"Arthritis Rheum"},{"key":"1035_CR6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.23523","volume":"59","author":"MM Ward","year":"2008","unstructured":"Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59:497\u2013503","journal-title":"Arthritis Rheum"},{"key":"1035_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B et al (2006) ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442\u2013452","journal-title":"Ann Rheum Dis"},{"key":"1035_CR8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199856020-00006","volume":"56","author":"E Toussirot","year":"1998","unstructured":"Toussirot E, Wendling D (1998) Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 56:225\u2013240","journal-title":"Drugs"},{"key":"1035_CR9","first-page":"16","volume":"65","author":"WP Arend","year":"2002","unstructured":"Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol Suppl 65:16\u201321","journal-title":"J Rheumatol Suppl"},{"key":"1035_CR10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/13543784.9.3.497","volume":"9","author":"R Fernandez-Botran","year":"2000","unstructured":"Fernandez-Botran R (2000) Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9:497\u2013514","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"1035_CR11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","volume":"33","author":"J Gratac\u00f3s","year":"1994","unstructured":"Gratac\u00f3s J, Collado A, Filella X, Sanmart\u00ed R, Ca\u00f1ete J, Llena J, Molina R, Ballesta A, Mu\u00f1oz-G\u00f3mez J (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927\u2013931","journal-title":"Br J Rheumatol"},{"key":"1035_CR12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2005.037465","volume":"65","author":"RJ Francois","year":"2006","unstructured":"Francois RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor in two patients with early disease and transforming growth factor in three more advanced cases. Ann Rheum Dis 65:713\u2013720","journal-title":"Ann Rheum Dis"},{"key":"1035_CR13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/13543784.9.3.497","volume":"9","author":"R Fernandez-Botran","year":"2000","unstructured":"Fernandez-Botran R (2000) Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9:497\u2013514","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"1035_CR14","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, Haibel H, S\u00f6rensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667\u20131675","journal-title":"Arthritis Rheum"},{"key":"1035_CR15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"1035_CR16","first-page":"670","volume":"44","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R et al (2005) Persistent clinical response to the anti-TNF-\u03b1 antibody infliximab in patients with ankylosing spondylitis over 3\u00a0years. Heumatology 44:670\u2013676","journal-title":"Heumatology"},{"key":"1035_CR17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/ard.2007.075879","volume":"67","author":"J Braun","year":"2008","unstructured":"Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor therapy with infliximab in patients with ankylosing spondylitis over 5\u00a0years: evidence for different types of response. Ann Rheum Dis 67:340\u2013345","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1035_CR18","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230\u20133236","journal-title":"Arthritis Rheum"},{"key":"1035_CR19","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ard.2007.078139","volume":"67","author":"JC Davis Jr","year":"2008","unstructured":"Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ et al (2008) Efficacy and safety of up to 192\u00a0weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346\u2013352","journal-title":"Ann Rheum Dis"},{"key":"1035_CR20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.21563","volume":"54","author":"H Haibel","year":"2006","unstructured":"Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H et al (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54:678\u2013681","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1035_CR21","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/ard.2009.121327","volume":"69","author":"N Barkham","year":"2010","unstructured":"Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, Cawkwell L, Emery P (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926\u20131928 Epub 2010 May 28","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1035_CR22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D Heijde Van der","year":"2008","unstructured":"Van der Heijde D, Landew\u00e9 R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324\u20131331","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1035_CR23","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","volume":"25","author":"DJ Rychly","year":"2005","unstructured":"Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25(9):1181\u20131192","journal-title":"Pharmacotherapy"},{"issue":"10","key":"1035_CR24","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","volume":"64","author":"J Askling","year":"2005","unstructured":"Askling J, Forted CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis 64(10):1414\u20131420","journal-title":"Ann Rheum Dis"},{"key":"1035_CR25","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S et al (1999) Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Lancet 354:1896\u20131900","journal-title":"Lancet"},{"issue":"1","key":"1035_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"key":"1035_CR27","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions version 5.0.1 [updated September 2008]. The Cochrane Collaboration","DOI":"10.1002\/9780470712184"},{"key":"1035_CR28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2106\/JBJS.H.01576","volume":"91","author":"N Simunovic","year":"2009","unstructured":"Simunovic N, Sprague S, Bhandari M (2009) Methodological issues in systematic reviews and meta-analyses of observational studies in orthopaedic research. J Bone Joint Surg [Am] 91:87\u201394","journal-title":"J Bone Joint Surg [Am]"},{"issue":"18","key":"1035_CR29","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349\u20131356","journal-title":"N Engl J Med"},{"issue":"12","key":"1035_CR30","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594\u20131600","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1035_CR31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ard.2010.139261","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799\u2013804","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1035_CR32","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D Heijde Van der","year":"2006","unstructured":"Van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X et al (2006) Etanercept study 314 investigators. Etanercept 50\u00a0mg once weekly is as effective as 25\u00a0mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572\u20131577","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1035_CR33","first-page":"741","volume":"49","author":"Feng Huang","year":"2010","unstructured":"Huang Feng, Zhang Jie, Huang JL, Wu DH, Li ZG, Chen SL et al (2010) A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis. Chin J Intern Med 49(9):741\u2013745","journal-title":"Chin J Intern Med"},{"issue":"10","key":"1035_CR34","first-page":"1911","volume":"32","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T et al (2005) Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32(10):1911\u20131917","journal-title":"J Rheumatol"},{"issue":"1","key":"1035_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.20075","volume":"51","author":"AJ Wanders","year":"2004","unstructured":"Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM (2004) Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum 51(1):1\u20138","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1035_CR36","first-page":"556","volume":"16","author":"LS Wang","year":"2007","unstructured":"Wang LS, Huang F, Zhang JL, Deng XH, Zhang YM, Zhang LY et al (2007) A cohort analysis of safety tumor necrosis factor-\u03b1 antagonists in the treatment of Chinese patients with ankylosing spondylitis. Chin J New Drugs 16(7):556\u2013561","journal-title":"Chin J New Drugs"},{"issue":"6","key":"1035_CR37","first-page":"396","volume":"10","author":"H Zhang","year":"2008","unstructured":"Zhang H, Deng XH, Zhang YM, Zhang JL, Huang F (2008) Studies on safety of etanercept in treatment of ankylosing spondylitis. Adverse Drug React J 10(6):396\u2013399","journal-title":"Adverse Drug React J"},{"issue":"1","key":"1035_CR38","first-page":"4","volume":"6","author":"YM Zhang","year":"2009","unstructured":"Zhang YM, Li XL, Wu HL, Zhang J (2009) Short-term safety of etanercept therapy in patients with ankylosing spondylitis. Chin J Drug Appl Monit 6(1):4\u201313","journal-title":"Chin J Drug Appl Monit"},{"key":"1035_CR39","unstructured":"Zhang J (2010) Initiatory approach on clinical assessment and evaluation of etanercept in the treatment of ankylosing spondylitis. Graduation dissertation for Master\u2019s degree"},{"key":"1035_CR40","first-page":"S178","volume":"20","author":"J Braun","year":"2002","unstructured":"Braun J, Golder W, Bollow M, Sieper J, van der Heijde D (2002) Imaging and scoring in ankylosing spondylitis. Clin Exp Rheumatol 20:S178\u2013S184","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1035_CR41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/keh475","volume":"44","author":"J Brandt","year":"2005","unstructured":"Brandt J, Listing J, Haibel H, S\u00f6rensen H, Schwebig A, Rudwaleit M et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44(3):342\u2013348","journal-title":"Rheumatology"},{"key":"1035_CR42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","volume":"53","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53:856\u2013863","journal-title":"Arthritis Rheum"},{"key":"1035_CR43","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","volume":"52","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor receptor fusion protein etanercept. Arthritis Rheum 52:1216\u20131223","journal-title":"Arthritis Rheum"},{"key":"1035_CR44","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.21790","volume":"54","author":"J Braun","year":"2006","unstructured":"Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, for the ASSERT Study Group et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646\u20131652","journal-title":"Arthritis Rheum"},{"key":"1035_CR45","doi-asserted-by":"crossref","unstructured":"McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al (2007) Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 11(28):1\u2013158, iii\u2013iv","DOI":"10.3310\/hta11280"}],"container-title":["European Journal of Orthopaedic Surgery & Traumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-012-1035-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00590-012-1035-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-012-1035-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T21:28:31Z","timestamp":1743629311000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00590-012-1035-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,29]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1007\/s00590-012-1035-7","relation":{},"ISSN":["1633-8065","1432-1068"],"issn-type":[{"value":"1633-8065","type":"print"},{"value":"1432-1068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,29]]}}}